The raise follows one that closed last year around this time for $1.25 million, which enabled 2-year-old NeuroFlow to make some key engineering hires and launch in beta its HIPAA-compliant platform, which helps motivate, track and encourage therapy patients between sessions. The technology is now in use in more than 100 clinics and hospitals in five continents, and the company of a dozen employees is on track to reach $1 million in annual revenue by the end of this year, cofounder Christopher Molaro said in a recent interview.
“With product demand accelerating and newfound applications for our technology, it was the right time to access supplementary investment from our strategic partners,” Molaro said in a prepared statement Monday about NeuroFlow’s latest round of funding.
In other words, NeuroFlow is preparing to bulk up, inspired by the traction with health care systems it achieved this year, he said, calling the new cash “an opportunity to scale quickly and decisively, as we expect to intensify our sales efforts during the final quarter of the year going into 2019.”
NeuroFlow is concluding a pilot with Smart Health Innovation Lab, an accelerator founded in 2017 through a collaboration between Capital Blue Cross, Penn Medicine Lancaster General Health and other health-care and start-up stakeholders to help bring new technologies to market.
NeuroFlow was inspired by Molaro’s five years serving as an officer in the Army, where he witnessed the mental health needs of soldiers.
About the Author